Protocol No.: NSABP-FB12

An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Principal Investigator
Kurian, Sobha
Phase
II
Age Group
Adult
Applicable Disease Site
Breast Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Kaitlyn Hager
Research Nurse

View on ClinicalTrials.gov